Terms: = Lung cancer AND LPP, Q93052, 4026, ENSG00000145012 AND Prognosis
3 results:
1. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract] [Full Text] [Related]
2. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459
[TBL] [Abstract] [Full Text] [Related]
3. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
[TBL] [Abstract] [Full Text] [Related]
